期刊文献+

荧光共振能量转移体系的均相免疫分析对前列腺癌诊断运用价值初探 被引量:2

Value of FRET homogeneous immunoassay on prostate cancer diagnosis
暂未订购
导出
摘要 目的:初步探索荧光共振能量转移体系(FRET)的均相免疫分析对前列腺癌诊断运用价值。方法:选择2013年5月至2014年9月我院收治的182例前列腺疾病患者,其中有31例患者为前列腺癌(PCa),151例患者为前列腺增生(BPH)。选择同期在我院进行健康体检的122例男性健康人群。采取FRET的均相免疫分析法对游离前列腺特异抗原(f PSA)和总前列腺特异抗原(t PSA)指标进行测定。分别观察三组人群的f PSA、t PSA、f/t PSA三项指标。依据PCa患者检测的TPSA值,采用TPSA〈4μg/L、4~10μg/L以及〉10μg/L三组指标,将其患者分为A、B、C组,从中对其三组之间的f PSA、t PSA、f/t PSA三项指标进行比较。当TPSA〈4μg/L时,比较正常人群和前列腺患者之间的三项指标。结果:三组人群的f PSA、t PSA、f/t PSA三项指标均存在明显的差异,差异具有统计学意义(P〈0.05)。三组患者的f PSA、t PSA、f/t PSA三项指标均有明显的差异,差异具有统计学意义(P〈0.05)。前列腺癌患者和正常人群t PSA〈4μg/L的f PSA、t PSA、f/t PSA指标比较存在明显的差异,具有统计学意义(P〈0.05)。结论:采用FRET的均相免疫分析法对f PSA和t PSA指标进行检测,能够准确、快速的提供有效的临床依据,在前列腺癌诊断中具有较高的诊断价值,值得广泛推广使用。 Objectives:To research the value of diagnosing prostate cancer using FRET homogeneous immunoassay.Methods:182 cases of prostate disease treated in our hospital from May 2013 to September 2014,including 31 patients with prostate cancer( PCa) and 51 patients benign prostatic hyperplasia( BPH),were selected.122 health men who received health examination at the same period in our hospital were selected as control group.FRET homogeneous immunoassay was adopted to measure free prostate-specific antigen( f PSA) and total prostate-specific antigen( t PSA) index.The f PSA,t PSA and F/T PSA levels of the three groups were recorded.For TPSA value of patients with PCa,TPSA 4μg/L,4 ~ 10μg/L and 10μg/L groups were divided as A,B,C groups.The f PSA,t PSA and F/T PSA of three groups were compared.When the TPSA 4μg/L,the three indicators of normal people and prostate patient were compared.Results:The f PSA,t PSA and F/T PSA of three groups were obviously different from each other,with statistically significant difference( P〈 0.05).The f PSA,t PSA,F/T PSA of three groups of patients had obvious differences,with statistically significant difference( P〈 0.05).When t PSA 4μg/L,f PSA,t PSA,F/T PSA of prostate cancer patients were obviously different from normal people,with statistically significant difference( P 〈0.05).Conclusions:The use of FRET homogeneous immunoassay to detect f PSA and t PSA indicators can accurately and quickly provide effective clinical basis and has high diagnostic value in the diagnosis of prostate cancer,which is worth widely application
出处 《中国性科学》 2016年第1期19-21,共3页 Chinese Journal of Human Sexuality
基金 浙江省杭州市科学技术委员会计划引导项目(杭科计[2014]2号)
关键词 荧光共振能量转移 均相免疫分析 前列腺癌 FRET Homogeneous immunoassay Prostate cancer
  • 相关文献

参考文献15

二级参考文献115

  • 1谢立平,秦杰,郑祥毅,沈华峰,陈昭典,蔡松良,张志根,丁伟,任国平,王丽君,余心如.481例前列腺癌患者年龄与病理构成分析[J].中华男科学杂志,2005,11(6):428-430. 被引量:37
  • 2陈卫中,倪宗瓒,潘晓平,刘元元,夏彦.用ROC曲线确定最佳临界点和可疑值范围[J].现代预防医学,2005,32(7):729-731. 被引量:213
  • 3朱一平,叶定伟.前列腺癌骨转移的治疗进展[J].国外医学(泌尿系统分册),2005,25(6):797-801. 被引量:3
  • 4Whiting P, Rutjes AWS, Reitsma JB, et al. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews[J].BMC Med Res Method- ol, 2003, 10(3):25-38.
  • 5Gregorio EP, Grando JP, Saqueti EE, et al.Comparison between PSA Density, Free PSA Percentage and PSA Density in the Transi- tion Zone in the Detection of Prostate Caneer in Patients with Se- rum PSA between 4 and 10 ng/mL[J]. Int Braz J Urol, 2007, 33 (2): 151-160.
  • 6Okegawa T, Kinjo M, Watanabe K, et al.The significance of the free-to-complexed prostate-specific antigen (PSA) ratio in prostate cancer detection in patients with a PSA level of 4. 1±10.0 ng/mL[J]. BJU Int, 2000,85(6):708-714.
  • 7Dincel C, Caskurlu T, Tasci AI, et al.Prospextive evaluation of pros- tate specific antigen(PSA),PSA density, free-to-total PSA ratio and a new formula(prostate malignancy index) for detecting prostate can- cer and preventing negative biopsies in patients with normal rectal examinations and intermediate PSA levels[J].Int Urology and Nephrol,1999,31 (4):497-509.
  • 8Fujinami K, Miura T, Takizawa A, et al. Comparison of value of free-to-total prostate specific antigen, prostate specific antigen den- sity and prostate specific antigen of transition zone for diagnosis of prostate cancer in patients with a PSA level of 4.1--10μg/L [J] . Nihon Hinyokika Gakkai Zasshi,2005,96(4):475-479.
  • 9Andile GL, Levin DL, Crawford ED, et al.Prostate cancer screening in the prostate, lung, colorectal and ovarian(PLCO) cancer screen- ing trial : findings from the initial screening round of a randomized trial[J]. J Natl Cancer Inst,2005,97(6):433--438.
  • 10i Smith DS, Catalona WJ, Keetch DW. Comparison of percent free and PSA density as meths to enhance to specificity of PSA screen- ing [J].J Urol, 1996,155:422.

共引文献113

同被引文献10

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部